1. Frick AC, Barber MD, Paraiso MF, Ridgeway B, Jelovsek JE, Walters MD. Attitudes toward hysterectomy in women undergoing evaluation for uterovaginal prolapse. Female Pelvic Med Reconstr Surg 2013;19:103-9.
2. Korbly NB, Kassis NC, Good MM, Richardson ML, Book NM, Yip S, et al. Patient preferences for uterine preservation and hysterectomy in women with pelvic organ prolapse. Am J Obstet Gynecol 2013;209:470e1-6.
4. Ridgeway B, Frick AC, Walter MD. Hysteropexy. A review. Minerva Ginecol 2008;60:509-28.
5. Gutman RE. Does the uterus need to be removed to correct uterovaginal prolapse? Curr Opin Obstet Gynecol 2016;28:435-40.
8. Frick AC, Walters MD, Larkin KS, Barber MD. Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. Am J Obstet Gynecol 2010;202:507e1-4.
9. Suh DH, Jeon MJ. Risk factors for the failure of iliococcygeus suspension for uterine prolapse. Eur J Obstet Gynecol Reprod Biol 2018;225:210-3.
10. Lin TY, Su TH, Wang YL, Lee MY, Hsieh CH, Wang KG, et al. Risk factors for failure of transvaginal sacrospinous uterine suspension in the treatment of uterovaginal prolapse. J Formos Med Assoc 2005;104:249-53.
11. Ridgeway BM. Does prolapse equal hysterectomy? The role of uterine conservation in women with uterovaginal prolapse. Am J Obstet Gynecol 2015;213:802-809.
14. Nesbitt RE Jr. Uterine preservation in the surgical management of genuine stress urinary incontinence associated with uterovaginal prolapse. Surg Gynecol Obstet 1989;168:143-7.
16. Dallas K, Elliott CS, Syan R, Sohlberg E, Enemchukwu E, Rogo-Gupta L. Association between concomitant hysterectomy and repeat surgery for pelvic organ prolapse repair in a cohort of nearly 100,000 women. Obstet Gynecol 2018;132:1328-36.
17. Jeng CJ, Yang YC, Tzeng CR, Shen J, Wang LR. Sexual functioning after vaginal hysterectomy or transvaginal sacrospinous uterine suspension for uterine prolapse: a comparison. J Reprod Med 2005;50:669-74.
18. Yazbeck C. Sexual function following hysterectomy. Gynecol Obstet Fertil 2004;32:49-54.
22. Ridgeway BM, Frick AC. Uterine conservation for the surgical treatment of uterovaginal prolapse. In: Walter Mark, Karram M, editors. Urogynecology and reconstructive pelvic surgery. Phildelphia (PA): Elsevier Saunders; 2015. p. 383-99.
24. Barranger E, Fritel X, Pigne A. Abdominal sacrohysteropexy in young women with uterovaginal prolapse: long-term follow-up. Am J Obstet Gynecol 2003;189:1245-50.
29. Food and Drug Administration (FDA). Urogynecologic surgical mesh: update on the safety and effectiveness of transvaginal placement for pelvic organ prolapse. Silver Spring (MD): FDA; 2011.
30. Food US; Drug Administration (FDA). FDA takes action to protect women’s health, orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices. Silver Spring (MD): FDA; 2019.
31. Maher C, Feiner B, Baessler K, Schmid C. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev 2013;(4):CD004014.